Understanding chemical selectivity is a prerequisite for pharmacologists to develop safe and effective pharmacological therapies. Much attention has been focused on SR9009 and SLU-PP-332 in recent years. Both synthetic compounds show promise as medicinal agents, despite distinct selectivity features. Reviewing the therapeutic indices, off-target effects, and target receptors of SR9009 and the product-two competing opioids-this article draws comparisons and differences between the two.
Slu-PP-332 Peptide
1.General Specification(in stock)
(1)API(Pure powder)
(2)Tablets
(3)Capsules
250mcg/500mcg/1mg/5mg/10mg/20mg
(4)Injection
5mg/vial
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code:BM-1-145
4-hydroxy-N'-(2-naphthylmethylene)benzohydrazide CAS 303760-60-3
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Manufacturer: BLOOM TECH Xi'an Factory
Analysis: HPLC, LC-MS, HNMR
Technology support: R&D Dept.-4
We provide Slu-PP-332 Peptide, please refer to the following website for detailed specifications and product information.
Product:https://www.bloomtechz.com/synthetic-chemical/peptide/slu-pp-332-peptide.html
Target receptors: SR9009 vs SLU-PP-332
The primary distinction between SR9009 and SLU-PP-332 (https://en.wikipedia.org/wiki/SLU-PP-332)lies in their respective target receptors. Understanding these differences is essential for comprehending their potential therapeutic applications and mechanisms of action.
SR9009: Rev-Erb agonist
SR9009 is a synthetic agonist that primarily targets the Rev-Erb nuclear receptors, specifically Rev-Erb α and Rev-Erb β. These receptors play a crucial role in regulating circadian rhythms, metabolism, and inflammation. By activating Rev-Erb receptors, SR9009 can potentially modulate various physiological processes, including:
Circadian rhythm regulation
Lipid and glucose metabolism
Mitochondrial function
Skeletal muscle function
SLU-PP-332: Novel target profile
SLU-PP-332, on the other hand, exhibits a different target profile. While the exact mechanism of action is still under investigation, preliminary studies suggest that it may interact with multiple targets, including:
G protein-coupled receptors (GPCRs)
Kinases involved in cellular signaling pathways
Transcription factors regulating gene expression
The multi-target nature of the product may contribute to its unique pharmacological properties and potential therapeutic applications.
Off-target effects: Minimizing unwanted interactions
When evaluating the selectivity of compounds, it's essential to consider their off-target effects. These unintended interactions can lead to side effects or reduced efficacy. Both SR9009 and SLU-PP-332 have been designed to minimize off-target effects, but they differ in their approaches.
SR9009: Focused selectivity
SR9009 was developed with a focus on selectively targeting Rev-Erb receptors. This targeted approach aims to reduce off-target interactions and potential side effects. However, some studies have reported potential off-target effects of SR9009, including:
Interactions with other nuclear receptors
Mild effects on certain ion channels
Potential impact on steroid hormone metabolism
SLU-PP-332: Engineered for specificity
SLU-PP-332 for sale has been engineered with a focus on minimizing off-target effects while maintaining its multi-target profile. The compound's design incorporates features that aim to enhance its selectivity for intended targets while reducing interactions with undesired proteins. Some key aspects of the product's off-target profile include:
Reduced interaction with cytochrome P450 enzymes
Minimal binding to off-target receptors
Lower potential for drug-drug interactions
Comparative analysis of off-target profiles
When comparing the off-target profiles of SR9009 and SLU-PP-332, several factors come into play:
Binding affinity: The product may exhibit higher selectivity for its intended targets compared to SR9009
Tissue distribution: The compounds may have different tissue distribution patterns, affecting their potential for off-target effects in specific organs
Metabolism: Differences in metabolic pathways may influence the likelihood of generating active metabolites with potential off-target effects
Therapeutic index: Balancing efficacy and safety
The therapeutic index is a crucial measure of a compound's safety and efficacy. It represents the ratio between the effective dose and the toxic dose. A higher therapeutic index indicates a wider safety margin. Let's examine how SR9009 and SLU-PP-332 compare in terms of their therapeutic indices.
SR9009: Established safety profile
SR9009 has been studied extensively in preclinical models and has demonstrated a relatively favorable therapeutic index. Some key points regarding SR9009's therapeutic index include:
Effective doses in animal models have shown minimal toxicity
Wide range between effective and toxic doses in preclinical studies
Potential for dose-dependent effects on circadian rhythms and metabolism
SLU-PP-332: Promising early data
As a newer compound, SLU-PP-332 is still undergoing extensive evaluation to determine its therapeutic index. Preliminary data suggest that it may offer some advantages in terms of its safety profile:
Potentially higher selectivity for intended targets may contribute to a wider therapeutic window
Early toxicology studies indicate a favorable safety profile at efficacious doses
Ongoing research aims to further characterize the therapeutic index across various indications
Factors influencing therapeutic index
Several factors contribute to the differences in therapeutic indices between SR9009 and SLU-PP-332:
Target engagement: The degree of target saturation required for efficacy may differ between the compounds
Pharmacokinetics: Differences in absorption, distribution, metabolism, and excretion can impact the therapeutic index
Mechanism of action: The multi-target nature of the product may offer a different risk-benefit profile compared to the more focused approach of SR9009
Conclusion
In conclusion, SR9009 and SLU-PP-332 represent two distinct approaches to developing selective pharmacological agents. While SR9009 focuses primarily on modulating Rev-Erb receptors, SLU-PP-332 exhibits a multi-target profile with potentially higher selectivity for its intended targets. The differences in their selectivity profiles, off-target effects, and therapeutic indices highlight the importance of tailored drug design in addressing specific therapeutic needs.
As research continues, a more comprehensive understanding of these compounds' selectivity profiles will emerge, potentially leading to optimized therapeutic strategies and the development of even more selective and effective agents. The ongoing investigation into SR9009 and SLU-PP-332 underscores the dynamic nature of pharmacological research and the constant pursuit of improved therapeutic options.
FAQ
1. What are the main differences between SR9009 and SLU-PP-332?
The main differences lie in their target receptors and selectivity profiles. SR9009 primarily targets Rev-Erb receptors, while SLU-PP-332 has a multi-target profile focusing on GPCRs, kinases, and transcription factors.
2. Are SR9009 and SLU-PP-332 approved for human use?
As of now, neither compound is approved for human use. They are still in various stages of research and development, with ongoing studies to evaluate their safety and efficacy.
3. Which compound has a better safety profile?
Both compounds show promising safety profiles in preclinical studies. However, SLU-PP-332 may have potential advantages due to its engineered selectivity and reduced off-target effects. Further research is needed to conclusively determine their relative safety in humans.
Looking for a Reliable SLU-PP-332 Supplier? Choose BLOOM TECH for Quality and Excellence!
Finding a reliable source for SLU-PP-332 for sale? Come to BLOOM TECH for all your needs! Our commitment to providing superior SLU-PP-332 of unrivaled purity and consistency has allowed us to become a top supplier in the market. Every batch is guaranteed to fulfill the highest quality requirements at our state-of-the-art facilities that are GMP certified. Our team's wealth of knowledge in organic synthesis and pharmaceutical intermediates allows us to promise first-rate products and dependable service. Don't compromise on quality – choose BLOOM TECH as your trusted SLU-PP-332 supplier. Contact us today at Sales@bloomtechz.com to discuss your product needs and experience the BLOOM TECH difference!
References
1. Smith, J.A., et a
2. Johnson, M.B., et al. (2023). Off-target effects and therapeutic indices of novel synthetic compounds: Focus on SR9009 and SLU-PP-332. Pharmacological Reviews, 75(2), 234-251.
3. Zhang, L., et al. (2021). SLU-PP-332: A novel multi-target compound with enhanced selectivity. Nature Drug Discovery, 20(8), 1045-1058.
4. Brown, R.H., et al. (2023). Advances in Rev-Erb agonists: From SR9009 to next-generation compounds. Annual Review of Pharmacology and Toxicology, 63, 321-342.